HCW Biologics (HCWB) stock rocketed higher on Friday following the release of the clinical-stage biopharmaceutical company’s Q1 2026 earnings report. This report began with revenue of $6.5 million, which was a massive improvement from the $5,065 reported in Q1 2025. The company attributed this revenue gain to license agreements.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
HCW Biologics also reported net income of $3.5 million in Q1 2026, which was a positive change from the company’s net loss of $2.2 million reported in Q1 2025. Investors will also note that the company reduced its research and development spending by 15% year-over-year to $1.3 million from $1.5 million. Its general and administrative expenses also decreased, this time by 18% to $1.8 million from $2.2 million.
HCW Biologics stock was up 196.35% in premarket trading on Friday, following a 3.55% fall yesterday. The stock has also decreased 65.26% year-to-date and 96.23% over the past 12 months.
HCW Biologics Guidance
HCW Biologics’ guidance for 2026 included stark warnings for investors. The company said “substantial doubt exists regarding its ability to continue as a going concern for at least 12 months from the issuance date of the audited financial statements, without additional funding or financial support.” However, the company did note early success in completing key elements of its financing plan.
In addition to this, HCW Biologics warned that HCWB stock is in danger of being delisted from the Nasdaq. The company needs to boost its share price to the $1 minimum required to maintain a listing. Interestingly, today’s earnings report acted as a catalyst that sent the stock to $1. The only question now is if the company can maintain that price, or if it will fall again.
Is HCW Biologics Stock a Buy, Sell, or Hold?
Turning to Wall Street, only one analyst has covered HCW Biologics over the past three months. Maxim Group analyst Michael Okunewitch holds a Buy rating and $2 price target for HCWB stock, representing a potential 493.47% upside for the shares. Additional analyst coverage may materialize following the company’s earnings report.
